Sun Pharmaceutical Industries Limited appears to be a financially stable company with a strong gross margin of 79.56% and EBITDA margin of 28.69%, indicating efficient operations. The company's ROE of 15.71% suggests decent profitability. However, the company's revenue and earnings growth rates are sluggish, with earnings growth being negative. The valuation appears to be rich, with a trailing P/E of 36.48 and forward P/E of 50.85. The company's debt-to-equity ratio of 3.26 is a concern, indicating high leverage.